Google
Trusted Resources: News & Events
Latest announcements and gatherings
Global Blood Therapeutics (GBT) announces upcoming data presentations supporting Voxelotor SCD program
Global Blood Therapeutics, Inc. (GBT) today announced that four abstracts related to the voxelotor program in sickle cell disease will be presented during the Foundation for Sickle Cell Disease Research’s (FSCDR) 12th Annual SCD Research and Educational Symposium in Washington, D.C., taking place June 15-17, 2018.
Four encore abstracts have been accepted, including three for oral presentation. Additionally, Kenneth R. Bridges, M.D., vice president, medical affairs at GBT, will be discussing voxelotor as part of the Investigational New Drugs, Therapeutic and Device Symposium on Friday, June 15, from 4:30-6:30 p.m. Eastern Time (ET). The abstracts are now available for symposium attendees through the FSCDR 2018 app.
+myBinderRelated Content
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseBackground: Deoxygenated sickle hemog...
-
GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)Global Blood Therapeutics, Inc. (GBT) to...
-
A single center experience of GBT440 treatment of severe anemia in sickle cell diseaseBackground: GBT440 is an oral, once-dail...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
-
Voxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data ShowGlobal Blood Therapeutics’ lead therap...
-
FDA agrees accelerated approval pathway for GBT’s voxelotorGlobal Blood Therapeutics, Inc. ...
-
Novartis acquires US pharma research firm Selexys PharmaceuticalsSwiss-based pharmaceuticals giant Novart...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.